Clinical trialNCT05347771Active, not recruitingPhase 2Interventional

Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment240Asthma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a multi-center, double-blind, placebo-controlled, randomized trial of dupilumab adjunctive therapy for prevention of asthma exacerbations in urban children and adolescents with T2-high exacerbation-prone asthma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Daniel J. Jackson, M.D.
University of Wisconsin School of Medicine and Public Health; Division of Allergy & Immunology
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Children'S Hospital Colorado: Allergy Program
Aurora, Colorado, United States
Children'S National Medical Center: Children'S Research Institute
Washington D.C., District of Columbia, United States
Ann & Robert H. Lurie Children'S Hospital of Chicago: Division of Allergy and Immunology
Chicago, Illinois, United States
Boston Children'S Hospital: Department of Immunology
Boston, Massachusetts, United States
Washington University at St. Louis
St Louis, Missouri, United States
Columbia University Medical Center: Division of Pediatric Pulmonology
New York, New York, United States
Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute
New York, New York, United States
Cincinnati Children'S Hospital Medical Center: Asthma Center
Cincinnati, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Dupilumab →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 4 May 2022
Primary completion: 31 Dec 2026
Completion: 15 Mar 2027
Last update posted: 20 Jan 2026
Registered enrollment: 240
Registry id: NCT05347771

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.